Tuangrat Phodha

Dr. Tuangrat Phodha


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2018 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
TPTuangrat Phodha
Tuangrat Phodha
ARArthorn Riewpaiboon
Arthorn Riewpaiboon
KMKumthorn Malathum
Kumthorn Malathum
Peter CoytePeter Coyte
Peter Coyte
Background – Antimicrobial resistance (AMR) is a major health threat worldwide as it brings about poorer outcomes and places economic burdens to society. This study aims to estimate the economic burdens from nosocomial infections (NI) caused by multi-drug resistant (MDR) bacteria in Thailand. Research design and methods – A retrospective cohort study was conducted at a tertiary hospital over 2011-2012. A multivariate log-linear regression model was used to estimate the excess treatment costs of AMR to those non-AMR patients. Results – Switching from a non-AMR case to an AMR infection case, resulted in 42% increase in expected average treatment costs per patient. The annual treatment from a hospital perspective and antibiotic costs associated with the management of AMR infections were estimated to be US$ 2.3 billion and US$ 262 million, respectively. The estimated annual benefit from eradicating AMR NI were US$ 4.2 billion from a societal perspective with the annual gains in Quality Adjusted Life Years (QALYs) of 0.6 million due to the absence of 111,295 AMR cases each year. Conclusions – Large amount of money were spent on treatment and antibiotic costs to manage AMR infections. Benefit of eliminating these infections was estimated and it would be highly cost-effective.

8 March 2019 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
TPTuangrat Phodha
Tuangrat Phodha
ARA. Riewpaiboon
A. Riewpaiboon
KMK. Malathum
K. Malathum
PCP. C. Coyte
P. C. Coyte
Antimicrobial resistance is a major health threat worldwide as it brings about poorer treatment outcome and places economic burden to the society. This study aims to estimate the annual relative increased in inpatient mortality from antimicrobial resistant (AMR) nosocomial infections (NI) in Thailand. A retrospective cohort study was conducted at Ramathibodi Hospital, Bangkok, Thailand, over 2008–2012. Survival model was used to estimate the hazard ratio of mortality of AMR relative to those patients without resistance (non-AMR) after controlling for nine potential confounders. The majority of NI (73.80%) were caused by AMR bacteria over the study period. Patients in the AMR and non-AMR groups had similar baseline clinical characteristics. Relative to patients in the non-AMR group, the expected hazard ratios of mortality for patients in the AMR group with Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus were 1.92 (95% CI 0.10–35.52), 1.25 (95% CI 0.08–20.29), 1.60 (95% CI 0.13–19.10) and 1.84 (95% CI 0.04–95.58), respectively. In the complete absence of AMR bacteria, this study estimated that annually, in Thailand, there would be 111 295 fewer AMR cases and 48 258 fewer deaths.

14 March 2024 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
PRParun Rutjanathamrong
Parun Rutjanathamrong
TPTuangrat Phodha
Tuangrat Phodha
TWThanawat Wongphan
Thanawat Wongphan
SSSirikorn Sujinnaprum
Sirikorn Sujinnaprum
NTNoppakun Thammatacharee
Noppakun Thammatacharee
Drug stores is an option that people can receive health care services for their common illnesses. This is the first study aims to estimate cost savings for 16 common illness symptoms to the Thailand’s health system. This study gathered retrospective secondary data from several studies and surveyed the median cost of medicines. Cost savings of care provided by pharmacists at drug stores in comparison to out-patient department (OPD) services at hospitals were quantified using cost of illness approach. The average number of hospital visits for treatment for 16 common illness symptoms was 2,356 visits per month. The estimation of the cost savings per visit from three perspectives, including government, patient, and societal, at tertiary care hospitals were 12.7–19.4, 12.7–25.6, and 18.9–25.6 USD, and at secondary care hospitals were 6.0–12.7, 6.0–18.9, and 12.2–18.9 USD. Every $1 reimbursed at drug stores will save additional costs in Thailand's health system, ranging from $0.04 to $0.24 and $0.02 to $0.16 at tertiary care hospitals and secondary hospitals, respectively. Pharmacy services for 16 common illness symptoms can clearly save costs.

11 February 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
KJKittiya Jantarathaneewat
Kittiya Jantarathaneewat
TPTuangrat Phodha
Tuangrat Phodha
KSKankanit Singhasenee
Kankanit Singhasenee
PKPanipak Katawethiwong
Panipak Katawethiwong
NSNuntra Suwantarat
Nuntra Suwantarat
AAAnucha Apisarnthanarak
Anucha Apisarnthanarak
Vancomycin Area Under the Curve (AUC) monitoring has been recommended to ensure successful clinical outcomes and minimize the risk of nephrotoxicity, rather than traditional trough concentration. However, vancomycin AUC monitoring by a pharmacist-led multidisciplinary team (PMT) has not been well established in Southeast Asia. This study was conducted at Thammasat University Hospital. Adult patients aged ≥ 18 years who were admitted and received intravenous vancomycin ≥48 h were included. The pre-PMT period (April 2020–September 2020) was defined as a period using traditional trough concentration, while the post-PMT period (October 2020–March 2021) was defined as a period using PMT to monitor vancomycin AUC. The primary outcome was the rate of achievement of the therapeutic target of an AUC/MIC ratio of 400–600. There was a significantly higher rate of achievement of therapeutic target vancomycin AUC during post-PMT period (66.7% vs. 34.3%, p < 0.001). Furthermore, there was a significant improvement in the clinical cure rate (92.4% vs. 69.5%, p < 0.001) and reduction in 30-day ID mortality (2.9% vs. 12.4%, p = 0.017) during the post-PMT period. Our study demonstrates that PMT was effective to help attain a targeted vancomycin AUC, improve the clinical cure rate, and reduce 30-day ID mortality. This intervention should be encouraged to be implemented in Southeast Asia.

1 February 2025 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
PAPoukwan Arunmanakul
Poukwan Arunmanakul
TPTuangrat Phodha
Tuangrat Phodha
SPSakkarin Pinta-Ay
Sakkarin Pinta-Ay
MNMantiwee Nimworapan
Mantiwee Nimworapan
APArintaya Phrommintikul
Arintaya Phrommintikul
Piyameth DilokthornsakulPiyameth Dilokthornsakul
Piyameth Dilokthornsakul
Purpose: To assess the budget impact and cost–benefit of incorporating sodium-glucose cotransporter-2 inhibitors (SGLT-2i) into the benefit package for patients with heart failure (HF) under the universal health coverage (UHC) in Thailand. Patients and Methods: A budget impact analysis and cost–benefit model were developed using a five-year time horizon from the payer perspective. Dapagliflozin 10 mg daily or Empagliflozin 10 mg daily was considered as an additional treatment to standard of care (SoC) for patients with HF, under the UHC. Two analytical frameworks were applied: (1) only medicine cost and (2) medicine cost and cost of hospitalization for HF (HHF) and urinary tract infection (UTI) admission as the adverse event of SGLT-2i. The net budget impacts (NBI) were calculated along with the HHF cost reduction and benefit–cost ratio. Results: The NBI in the first year in only medicine cost for dapagliflozin was 12,535 million Thai baht (THB) and that for empagliflozin was 13,265 million THB. The NBIs, when considering HHF and UTI admission costs, were 7661 and 7407 million THB in the first year. The prices of dapagliflozin and empagliflozin should be reduced by 57.13% and 52.07% to reach a budget impact of 500 million THB. The benefit–cost ratio was 0.396 for dapagliflozin and 0.456 for empagliflozin. Conclusion: Incorporating SGLT-2i into the UHC would significantly impact the healthcare budget. Policymakers should consider this valuable evidence.

3 December 2024 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
POPiyapat Owat
Piyapat Owat
CSChaoncin Sooksriwong
Chaoncin Sooksriwong
HRHataiwan Ratanabunjerdkul
Hataiwan Ratanabunjerdkul
TPTuangrat Phodha
Tuangrat Phodha
Drug expenditure is an important part of health expenditure. Managed Entry Agreement (MEA) is a common strategy implemented in many countries, such as the United States, the United Kingdom, and the European countries to control drug expenditures, especially for new and high-cost drugs. This study aims to explore the appropriate MEA technique for reaching the lowest cost of drug procurement under specified uncertainty of the high-cost drug. The cost of drug procurement varied by the MEA techniques will be investigated in the quantitative analysis based on MEA taxonomies and uncertainty in terms of price, use, and effectiveness. Then, the content analysis will be employed to the qualitative analytical part to summarise the matching of appropriate MEA technique with the characteristics of high-cost drug to lower the cost of drug procurement and increase access to high-cost drugs. The rationales for each MEA technique selection are similar across their objectives. MEA can help reduce drug expenditures. Therefore, the budget in health care system could be sustainable and the patient access to high-cost drug could be increased. However, it might not be suitable for some circumstances and should not be implemented to determine drug price or used as regular reimbursement.